Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Hansoh Biomedicine Technology
Shanghai, Shanghai, Chinahansoh.cn ↗
- Ownership
- Private
- Employees
- ~7500
- Development stage
- Other
01
Overview
Hansoh currently has over 40 innovative drug candidates with more than 70 clinical trials underway; 7 innovative drugs are approved and marketed, covering oncology, infection, CNS, metabolic, and autoimmune diseases. HS-20093 (B7-H3 ADC) shows promising results in early clinical trials for multiple solid tumors.
- Therapeutic areas
- NephrologyEndocrinologyInfectious DiseasesDermatologyOncologyNeurology
- Modalities
- Small moleculeAntibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodyFusion proteinsiRNAPeptidesBiologic
- Industry
- Biotech
02
Partnerships
GSK (HS-20093, HS-20089 licensing)MSD (Merck & Co.)Regeneron
Beyond the preview
Go deeper on Shanghai Hansoh Biomedicine Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Hansoh Biomedicine Technology.